The eortc melanoma group exchange program: Evaluation of a multicenter monoclonal antibody study
- 17 July 1991
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 48 (6) , 836-847
- https://doi.org/10.1002/ijc.2910480609
Abstract
In the framework of the European Organisation for Research and Treatment of Cancer (EORTC), the Immunology and Pathology Subgroups of the Malignant Melanoma Cooperative Group undertook a large multicenter monoclonal antibody (MAb) study. Fourteen laboratories from 7 European countries tested a panel of 23 MAbs for immunohistological staining reactivity for malignant and non-malignant lesions involving the melanocytic lineage. A standardized im-munoperoxidase procedure was used and the results were evaluated using a standard protocol and data evaluation form developed in collaboration with the EORTC Data Center. According to this analysis, the antibodies in the panel could be classified into 3 main groups. The first group of MAbs includes those antibodies which stained the majority (>80%) of all primary tumors, irrespective of their Breslow thickness and the majority of metastatic lesions. In addition, these MAbs stained a high percentage of cells within a given lesion. Several antibodies of Group I were likewise reactive with the majority of naevoblasts and with normal melanocytes. The second group of MAbs included antibodies reacting only with a limited number of primary melanomas and metastatic lesions. Antibodies of Group II reacted only weakly, if at all, with normal melanocytes or naevocytes. The percentage of cells within a malignant lesion stained by these MAbs was always rather tow. The MAb group III detected surface structures whose expression appeared to be related to tumor progression; they did not react or reacted only weakly with naevi, and they all reacted with a small number of early primary melanomas (<0.75 mm). The number of lesions stained increased with increasing Breslow thickness. Our study suggests that the application of a panel of well defined MAbs might be of diagnostic and prognostic value in evaluating malignant melanoma.Keywords
This publication has 28 references indexed in Scilit:
- Monoclonal Antibody PAL-M1 Recognizes the Transferrin Receptor and Is a Progression Marker in Melanocytic LesionsJournal of Investigative Dermatology, 1990
- Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase.The Journal of Experimental Medicine, 1988
- Activities of the EORTC Breast Cancer Co-operative Group: an overviewEuropean Journal of Cancer and Clinical Oncology, 1988
- Monoclonal Antibodies Selected to Discriminate Between Malignant Melanomas and Nevocellular NeviJournal of Investigative Dermatology, 1985
- A tumor-associated antigen expressed in melanoma cells with lower malignant potentialInternational Journal of Cancer, 1985
- Biochemical characterization and cellular localization of a formalin‐resistant melanoma‐associated antigen reacting with monoclonal antibody NKI/C‐3International Journal of Cancer, 1985
- In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.The Journal of Experimental Medicine, 1985
- Acquired Precursors of Cutaneous Malignant MelanomaNew England Journal of Medicine, 1985
- Characterization of a Monoclonal Antibody (A12) that Defines a Human Acute Lymphoblastic Leukemia-Associated Differentiation AntigenHybridoma, 1983
- Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis‐inhibiting effect of 7 monoclonal antibodiesEuropean Journal of Immunology, 1982